Cargando…
COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
by the American Academy of Dermatology, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963969/ https://www.ncbi.nlm.nih.gov/pubmed/35364214 http://dx.doi.org/10.1016/j.jaad.2022.02.070 |
| _version_ | 1784678105419350016 |
|---|---|
| author | Yang, Qian Jiang, Qi Man Niu, Man Fan, Guo Zhen Hu, Peng |
| author_facet | Yang, Qian Jiang, Qi Man Niu, Man Fan, Guo Zhen Hu, Peng |
| author_sort | Yang, Qian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8963969 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | by the American Academy of Dermatology, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89639692022-03-30 COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated Yang, Qian Jiang, Qi Man Niu, Man Fan, Guo Zhen Hu, Peng J Am Acad Dermatol JAAD Online by the American Academy of Dermatology, Inc. 2022-07 2022-03-29 /pmc/articles/PMC8963969/ /pubmed/35364214 http://dx.doi.org/10.1016/j.jaad.2022.02.070 Text en © 2022 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | JAAD Online Yang, Qian Jiang, Qi Man Niu, Man Fan, Guo Zhen Hu, Peng COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title | COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title_full | COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title_fullStr | COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title_full_unstemmed | COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title_short | COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated |
| title_sort | covid-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: a personalized regimen should be formulated |
| topic | JAAD Online |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963969/ https://www.ncbi.nlm.nih.gov/pubmed/35364214 http://dx.doi.org/10.1016/j.jaad.2022.02.070 |
| work_keys_str_mv | AT yangqian covid19vaccinationinpatientswithimmunemediatedinflammatorydiseasesreceivingrituximabapersonalizedregimenshouldbeformulated AT jiangqi covid19vaccinationinpatientswithimmunemediatedinflammatorydiseasesreceivingrituximabapersonalizedregimenshouldbeformulated AT manniuman covid19vaccinationinpatientswithimmunemediatedinflammatorydiseasesreceivingrituximabapersonalizedregimenshouldbeformulated AT fanguozhen covid19vaccinationinpatientswithimmunemediatedinflammatorydiseasesreceivingrituximabapersonalizedregimenshouldbeformulated AT hupeng covid19vaccinationinpatientswithimmunemediatedinflammatorydiseasesreceivingrituximabapersonalizedregimenshouldbeformulated |